Society for Translational Oncology


Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist. RSS Feed URL

Society for Translational Oncology navigateright Episode

Cross-resistance in Small Cell Lung Cancer

We have generated a panel of 66 patient-derived xenograft models (PDXs) of SCLC from biopsy specimens and circulating tumor cells (CTCs). These models stably maintain somatic genomic alterations from patients, and faithfully mirror their responses to DNA damaging therapies. The strongest correlate with sensitivity to both regimens was basal expression of interferon-stimulated genes (ISG’s), and cross-resistance was marked by low basal ISG expression. This result was surprising, as xenografts were grown and tested in severely immunocompromised mice. Investigation of the ISG signature presents a novel opportunity to dissect the molecular underpinnings of cross-resistance, a problem that has beleaguered management of SCLC for over three decades.

Video Overview:

Benjamin Drapkin, MD, PhD

MGH Cancer Center

STO gratefully acknowledges educational grants in partial support of this activity from:
Agios Pharmaceuticals
Celgene Corporation
Novartis Pharmaceuticals Corp.
Pfizer Inc.